The United Kingdom's departure from the European Union has created significant obstacles for pediatric cancer patients seeking access to innovative treatments. Medical experts highlight how Brexit-related regulatory changes and increased pharmaceutical costs are delaying critical clinical trials for childhood brain tumors. The situation has prompted calls for policy reform to restore collaborative healthcare frameworks with European institutions and expedite delivery of potentially life-saving therapies to vulnerable young patients.

Summary auto-generated by AI from the original publisher's content. Editorial standards.